Business Context and Reporting Period
This is Immudyne, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2013—not a filing identified as LifeMD, Inc. Immudyne develops, manufactures, and sells yeast beta-glucan nutraceutical and cosmetic products.
Financial Results
| Metric | Q3 2013 | Q3 2012 | Nine months 2013 | Nine months 2012 |
|---|---|---|---|---|
| Sales | $94,676 | $152,115 | $647,837 | $558,218 |
| Gross profit | $77,201 | $98,261 | $523,656 | $367,440 |
| Gross margin | 81.5% | 64.6% | 80.8% | 65.8% |
| Operating loss | $(168,666) | $(163,641) | $(259,608) | $(415,175) |
| Net loss | $(139,366) | $(159,341) | $(196,708) | $(374,485) |
| Operating cash flow | Not separately reported | Not separately reported | $(112,478) | $(165,473) |
At September 30, 2013, cash was $46,652, current assets were $178,008, and current liabilities were $217,483; the company reported negative working capital of $39,475 and a current ratio of 0.8 to 1. Total liabilities were $252,183, including a $10,200 director advance and a $34,700 deferred tax liability. The filing reports no interest expense for the 2013 nine-month period.
Changes Versus Prior Period
Third-quarter sales fell 38%, which management attributed to depleted inventory during product rebranding and inventory rebuilding; the replacement inventory was received in early November. Nine-month sales rose 16%, driven by first-half demand for topical products. Gross margin improved in both comparisons, mainly because of lower laboratory and manufacturing costs. Nine-month net loss narrowed 47%, while quarterly net loss narrowed 13%; the quarterly operating loss nevertheless increased modestly. Nine-month operating expenses were approximately flat, with higher compensation and general and administrative costs largely offset by lower professional fees.
Outlook, Risks, and Unusual Items
- Going concern and funding: The filing states that substantial doubt exists about the company’s ability to continue as a going concern. Management expected to need additional capital for 2013 and 2014 and planned to rely on increased sales, equity issuance, or debt financing; there is no assurance that funding will be available on acceptable terms. Continued operations also depend on higher sales and financial support from officers or directors.
- Customer concentration: One customer represented 73% of third-quarter sales and 80% of nine-month sales in 2013, versus 76% and 77% in the comparable 2012 periods.
- Related-party royalty: A skin-care royalty agreement requires payments equal to 8% of certain sales. Approximately $114,000 was accrued at quarter-end, with about $75,000 of commitment remaining. The president has a 60% interest in the royalties and deferred payment without interest until the company can afford to pay.
- Other income: License-fee receipts contributed $25,000 in the quarter and $50,000 in the nine-month period; the filing says timing affected the year-over-year comparison. A further $50,000 remained payable under the patent-license settlement at September 30, 2013.
- Commitments and risks: Future minimum plant lease payments totaled $111,680. Management identified marketing costs, intellectual-property protection, and potential changes in government regulation as important operating risks. No material legal proceedings were identified.
- Controls: Management concluded disclosure controls were ineffective, citing material weaknesses including inadequate segregation of duties, insufficient written accounting and reporting procedures, inadequate computer-system security and disaster-recovery planning, and no written whistleblower policy. Remediation was planned, subject to funding.
Important Facts for Investors to Verify
- Confirm the intended issuer: the supplied filing names Immudyne, Inc., not LifeMD, Inc.
- Assess the company’s near-term cash needs, ability to raise capital, and whether going-concern uncertainty has changed.
- Verify inventory availability and sales recovery after the reported early-November inventory receipt.
- Evaluate reliance on the largest customer and the effect of any change in that relationship.
- Review accrued and deferred related-party royalties, outstanding lease commitments, and plans to remediate control weaknesses.
- Check the filing’s reported figures against the underlying statements: its MD&A contains an apparent inconsistency in prior-year general and administrative expense.